TOKYO, June 4, 2026 /PRNewswire/ -- PENTAX Medical announced the renewal of their longstanding collaboration with FUJIFILM Corporation in the field of Endoscopic Ultrasound (EUS). Effective April 2026, the renewed agreement establishes a framework that reinforces the long-term cooperative relationship between the two companies, for the supply of ultrasound diagnostic equipment and related products.
The collaboration covers the ARIETTA™ 850, ARIETTA™ 750, and ARIETTA™ 65 ultrasound scanners, which are used in combination with PENTAX Medical's EUS‑J10 and EB‑J10 line of echoendoscopes as well as the INSPIRA™ video processor. Together, these integrated solutions have long been recognized as market leaders in Endoscopic Ultrasound, providing physicians with advanced visualization, precision, and access that are critical to successful patient outcomes.
Importantly, the renewed agreement ensures continuity and reliability for customers, with the ability to provide product support for over a decade, reinforcing PENTAX Medical commitments to long-term clinical confidence and investment protection for our customers.
With decades of experience in echoendoscope development and ultrasound imaging innovation, this collaboration delivers seamless system compatibility, dependable performance, and consistent clinical excellence. "We are excited to continue this long-term relationship, which allows PENTAX Medical to continue providing our valued customers with a world-class clinical experience," said Dominique Vincent, Global President of PENTAX Medical. "Our echoendoscopes are uniquely calibrated to work seamlessly with the ARIETTA ultrasound systems, and this agreement enables us to continue delivering integrated solutions that physicians trust—today and well into the future."
This milestone reflects PENTAX Medical's commitment to advancing next‑generation echoendoscope technologies that will drive the evolution of Endoscopic Ultrasound, backed by a foundation of first-to-market-innovations, quality, and sustained customer support.
About PENTAX Medical
PENTAX Medical, a division of the HOYA Group, is a global player in flexible, reusable endoscopy solutions. The company develops, manufactures, distributes, and services endoscopic equipment worldwide. PENTAX Medical is committed to delivering intuitive, flexible endoscopy solutions that empower healthcare professionals to provide outstanding care. Its mission is to maintain product excellence while collaborating closely with clinical partners to understand and address their daily challenges, workflows, and goals. At the core of this mission is a commitment to reliability and high-quality imaging—fundamental requirements for clinical performance. Building on this foundation, PENTAX Medical delivers solutions that integrate seamlessly into clinical practice, supported by ergonomic and ease-of-use innovations, practical clinical education, and personalized, attentive customer support.
For more information, please visit our website: https://www.pentaxmedical.com
About HOYA
HOYA Corporation, founded in Tokyo in 1941, is a global leader in healthcare and technology innovation. HOYA provides advanced products for life care, including eyeglass lenses, intraocular lenses, and medical endoscopes, as well as high-precision components that support today's information society, such as mask blanks for semiconductor manufacturing, glass substrates for hard disk drives, and optical components for imaging systems. With over 150 offices worldwide and a team of around 38,000 professionals, HOYA is committed to advancing technologies that contribute to a more sustainable future. For more details, please visit our website (https://www.hoya.com/en/).
View original content:https://www.prnewswire.co.uk/news-releases/pentax-medical-and-fujifilm-corporation-renew-ultrasound-diagnostic-business-collaboration-agreement-302790954.html
Die naoo AG hat ihren ersten konsolidierten Konzernabschluss nach International Financial Reporting Standards (IFRS) vorgelegt und damit einen weiteren Schritt in Richtung Kapitalmarktreife vollzogen. Der Betreiber der Social-Media- und Commerce-Plattform mit Sitz in Zug/Zürich erzielte im Geschäftsjahr 2025 einen operativen Umsatz von 6,0 Millionen Schweizer Franken. Unter dem Strich weist die Gruppe ein positives Konzernergebnis von 0,3 Millionen Franken aus.
Die Umstellung auf IFRS soll die Finanzberichterstattung professionalisieren und die Vergleichbarkeit für institutionelle Investoren erhöhen. Laut Unternehmen ist das ausgewiesene Ergebnis wesentlich von nicht zahlungswirksamen Effekten aus der erstmaligen IFRS-Anwendung beeinflusst. Diese stehen insbesondere im Zusammenhang mit der Kaufpreisallokation im Rahmen der Integration von Kingfluencers. Bereinigt um diese Effekte sieht sich die Gruppe weiterhin in einer planmässigen Investitions- und Skalierungsphase.
Per Bilanzstichtag verfügte die naoo Gruppe über ein Eigenkapital von 7,9 Millionen Franken und damit über eine deutlich gestärkte Bilanzbasis. Zur Verbesserung der Kapitalstruktur trug auch die im Dezember 2025 vollzogene Umwandlung von Darlehen in Eigenkapital bei. Die Massnahme reduziert Verschuldung und erhöht die Eigenkapitalquote, was die finanzielle Flexibilität des Unternehmens stützt.
Strategisch setzte naoo im Geschäftsjahr 2025 auf die Integration von Kingfluencers. Durch die Verbindung von Plattformtechnologie, einem Creator-Ökosystem und etablierten Kundenbeziehungen will die Gruppe die Grundlage für eine weitere kommerzielle Skalierung legen. Im Zuge der Integration wurden im Berichtsjahr erste gemeinsame Wachstumsinitiativen angestossen. Das Management positioniert naoo damit als Social-Commerce-Anbieter, der Technologie, Inhaltserstellung und Markenbeziehungen stärker verzahnt.
